|
|
|
|
| LEADER |
03776nmm a2200325 u 4500 |
| 001 |
EB001824100 |
| 003 |
EBX01000000000000000990546 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
180604 ||| eng |
| 020 |
|
|
|a 9783319758367
|
| 100 |
1 |
|
|a Pollard, John
|e [editor]
|
| 245 |
0 |
0 |
|a Targeting the DNA Damage Response for Anti-Cancer Therapy
|h Elektronische Ressource
|c edited by John Pollard, Nicola Curtin
|
| 250 |
|
|
|a 1st ed. 2018
|
| 260 |
|
|
|a Cham
|b Humana
|c 2018, 2018
|
| 300 |
|
|
|a IX, 401 p. 80 illus., 52 illus. in color
|b online resource
|
| 505 |
0 |
|
|a 1. Targeting DNA repair in anti-cancer treatments -- 2. The DNA damage response: roles in cancer etiology and treatment -- 3. Control of DNA Replication by ATR -- 4. Targeting ATR for cancer therapy: Profile & expectations for ATR inhibitors -- 5. Targeting ATR for cancer therapy: ATR-targeted drug candidates -- 6. ATM: its recruitment, activation, signalling and contribution to tumour suppression -- 7. Pre-clinical profile and expectations for pharmacological ATM inhibition -- 8. Targeting ATM for cancer therapy: Prospects for drugging ATM -- 9. Targeting Chk1 for cancer therapy: rationale, progress and prospects -- 10. Preclinical profiles and contexts for CHK1 and CHK2 inhibitors -- 11. Clinical development of CHK1 inhibitors -- 12. Established and emerging roles of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) -- 13. Targeting DNA-PK as a therapeutic approach in oncology -- 14. Dbait: a new concept of DNA repair pathways inhibitor from bench to bedside -- 15. Alternative Non Homologous End-joining: Mechanisms and Targeting Strategies in Cancer
|
| 653 |
|
|
|a Clinical Genetics
|
| 653 |
|
|
|a Medical genetics
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Cancer Biology
|
| 700 |
1 |
|
|a Curtin, Nicola
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Cancer Drug Discovery and Development
|
| 028 |
5 |
0 |
|a 10.1007/978-3-319-75836-7
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-75836-7?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 082 |
0 |
|
|a 571.978
|
| 520 |
|
|
|a Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agentsthat may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit
|